VANCOUVER, June 28 /PRNewswire-FirstCall/ - Dragon
Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD;
OTCBB: DRUG) announced that its Special Meeting of Shareholders
will be held on Tuesday, July 20,
2010 at 10:30 a.m., Pacific
Time at the Company's corporate office located at Suite 310,
650 West Georgia Street, Vancouver,
British Columbia, Canada V6B 4N9. Only shareholders of
record of as of May 28, 2010 will be
entitled to vote upon the proposed Agreement and Plan of Merger by
and among Dragon, Chief Respect Limited, a Hong Kong corporation, Datong Investment Inc.,
a Florida corporation and
subsidiary of Chief Respect Limited, and Mr. Yanlin Han, pursuant to which Datong Investment
Inc. will merge with and into Dragon and each holder of Dragon
shares of common stock, excluding Mr. Han, will receive
$0.82 per share. Notice of the
meeting and accompany proxy statement are being mailed to
shareholders on June 28, 2010.
Additional Information and Where to Find It
In connection with the proposed merger, the Company has filed
with the Securities and Exchange Commission (the "SEC") a Schedule
13E-3, and a definitive proxy statement for the meeting of
stockholders of the Company to be convened to approve the merger.
BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, DRAGON'S
STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER
DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY
BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
MERGER. Stockholders may obtain a free copy of the proxy statement,
and other documents filed by us with the SEC, at the SEC's web site
at http://www.sec.gov. Free copies of the proxy statement and our
other filings with the SEC may also be obtained from us. Free
copies of our filings may be obtained by directing a request to
Dragon Pharmaceutical, Inc., 650 West Georgia Street, Suite 310,
Vancouver, British Columbia,
Canada V6B 4N9 Attention: Maggie
Deng, Secretary. Copies of the proxy statement may also be
obtained at our website, www.dragonpharma.com.
About Dragon Pharmaceutical Inc.
Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer
and distributor of a broad line of high-quality antibiotic products
including Clavulanic Acid, an API to combine with Amoxicillin to
fight resistance, and 7-ACA, a key intermediate to produce
cephalosporin antibiotics, and formulated cephalosporin antibiotic
drugs. To learn more about Dragon Pharmaceutical Inc., please visit
www.dragonpharma.com.
SOURCE Dragon Pharmaceutical Inc.